Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Short-term Investments (2018 - 2025)

China SXT Pharmaceuticals has reported Short-term Investments over the past 6 years, most recently at $31001.0 for Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $31001.0; the TTM value through Sep 2025 reached $31001.0, changed N/A, while the annual FY2025 figure was $30413.0, 344.5% up from the prior year.
  • Short-term Investments for Q3 2025 was $31001.0 at China SXT Pharmaceuticals, up from $30413.0 in the prior quarter.
  • Over five years, Short-term Investments peaked at $45297.0 in Q1 2022 and troughed at $6842.0 in Q1 2024.
  • A 4-year average of $27900.0 and a median of $30413.0 in 2025 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: surged 74.58% in 2022 and later soared 344.5% in 2025.
  • Year by year, Short-term Investments stood at $25947.0 in 2021, then surged by 74.58% to $45297.0 in 2022, then tumbled by 84.9% to $6842.0 in 2024, then skyrocketed by 353.1% to $31001.0 in 2025.
  • Business Quant data shows Short-term Investments for SXTC at $31001.0 in Q3 2025, $30413.0 in Q1 2025, and $6842.0 in Q1 2024.